Rapport Therapeutics, Inc. Common Stock (RAPP)
Rapport Therapeutics, Inc. Common Stock operates in the Biotechnology industry of the Healthcare sector, headquartered in Boston, MA, US. The stock last traded at $47.32, down 3.07% on the session, giving a market capitalisation of $2.26B. On trailing twelve-month figures it carries a trailing P/E of -15.57, a net margin of -685.8%. Its beta of 0.97 implies it has historically moved less than the broad market.
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
Rapport Therapeutics, Inc. Common Stock is most often compared with the following Healthcare names: